**The Mechanisms and Role of HIF-PHIs in Patients with CKD and Anemia:**

**Advances in the Therapeutic Landscape**

**Tweetorial #1 References**

**Tweet 3:**

Stauffer ME, Fan T. *PLOS One*. 2014;9(1):e84943.

Sato Y, et al. *Clin Exp Nephrol*. 2018;22(2):388-394.

Covic A, et al. *Adv Ther*. 2017;34:1662-1672.

Thorp ML, et al. *Nephrology*. 2009;14(2):240-246.

**Tweet 5:**

<https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-modified-dosing-recommendations-improve-safe-use-erythropoiesis#table>

**Tweet 6:**

Kuwahara M, et al. *Clin Exp Nephrol*. 2015;19(4):598-605.

Locatelli F, et al. *Am J Nephrol*. 2017;45(3):187-199.